IMP3 (IGF2BP3) Human shRNA Lentiviral Particle (Locus ID 10643)

CAT#: TL312221V

IGF2BP3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL312221A virus into HEK293 cells. TL312221A virus was prepared using lenti-shRNA TL312221A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL312221B virus into HEK293 cells. TL312221B virus was prepared using lenti-shRNA TL312221B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL312221C] virus into HEK293 cells. [TL312221C] virus was prepared using lenti-shRNA [TL312221C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL312221D] virus into HEK293 cells. [TL312221D] virus was prepared using lenti-shRNA [TL312221D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 10643
• Synonyms: CT98; IMP-3; IMP3; KOC; KOC1; VICKZ3
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_006547, NM_006547.1, NM_006547.2, BC065269, BC019258, BC051296, NM_006547.3
• UniProt ID: O00425
• Summary: The protein encoded by this gene is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. The encoded protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism. A pseudogene exists on chromosome 7, and there are putative pseudogenes on other chromosomes. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).